Clinical Trials Browser

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00490776 2021-08-18

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Phase 2 Terminated

9 enrolled 6 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT03837457 2020-11-19

PRISM

Phase 2 Terminated

8 enrolled

DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT02542124 2018-11-16

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

Phase 2 Unknown

10 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00091559 2017-04-05

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Phase 2 Completed

74 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00611208 2016-11-29

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

Phase 2 Completed

32 enrolled

DermatologicLymphoidOther hematologic neoplasm

Mycosis Fungoides, Sezary Syndrome, Leukemia, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT02943642 2016-10-25

Resimmune®

Phase 2 Unknown

162 enrolled

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00431912 2015-07-08

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

Phase 2 Completed

25 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00535470 2012-08-09

An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides

Phase 2 Completed

100 enrolled

Lymphoid

Mycosis Fungoides

NCT00501735 2012-01-23

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Phase 2 Completed

144 enrolled

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

Clinical Trials

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

RESMAIN

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

CTCL

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

SOLAR

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

PRISM

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

Resimmune®

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma